Targeting intracellular PD-L1 has been shown to promote antitumor immune responses in some mouse tumor models [15,47,48], and nuclear PD-L1 upregulates several genes involved in immunosuppression, including PDCD1LG2, BIRC3, RELB, and VSIR [15,49,50]. The gene discussed is BIRC3; the disease is neoplasm.